Lunit's AI Cancer Detection Platform Receives FDA Clearance for Lung and Breast Screening
Lunit's FDA clearance validates the global competitiveness of Korean AI medtech and could accelerate the adoption of AI-assisted cancer screening across APAC's healthcare systems.
Lunit secured FDA 510(k) clearance for its AI lung and breast cancer detection platforms, enabling market entry into the United States.
South Korean AI medical imaging company Lunit has received FDA 510(k) clearance for its Lunit INSIGHT CXR and Lunit INSIGHT MMG products, which use deep learning to detect lung nodules and breast cancer in X-ray and mammography images. The clearance opens the US market for Lunit, which already has regulatory approvals in 50+ countries and partnerships with GE HealthCare and Fujifilm.
Lunit's FDA clearance validates the global competitiveness of Korean AI medtech and could accelerate the adoption of AI-assisted cancer screening across APAC's healthcare systems.
Where this signal fits in the broader landscape.
No recent signals tracked yet.
https://www.lunit.io/en/newsroom
Read Full SourceGet curated intelligence delivered to your inbox. No spam, unsubscribe anytime.
Sign in to save notes on signals.
Sign In